ArticleNPJ biofilms and microbiomes2026
Network-level divergence in cyclic di-GMP signalling drives ecological versatility in Acinetobacter baumannii.
Article in NPJ biofilms and microbiomes, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
Abstract
Second messenger signalling pathways are known to play a fundamental role in governing bacterial physiology and mediating rapid adaptive responses to stimuli. Despite the extensive characterisation of second messenger signalling systems such as the cyclic di-GMP (c-di-GMP) signalling system in pathogens, relatively little is known about the role of these pathways in the priority pathogen Acinetobacter baumannii. To address this, we carried out a comprehensive exploration of c-di-GMP signalling across multiple modern A. baumannii clinical isolates. We elucidate this second messenger's regulon and its role in biofilm formation and other virulence-associated behaviours. Furthermore, we demonstrate that specific enzymes controlling c-di-GMP levels are associated with specific international clones, with PdeD being identified as the primary functional phosphodiesterase in the worldwide prevalent International Clone I. Further characterisation of PdeD revealed it as a key regulatory node, controlling host colonisation in a murine model and persistence in the hospital environment. This indicates that the physiological control exerted by PdeD represented a distinctive advantage for the global dissemination of this lineage. Overall, this work uncovers the core regulatory role of c-di-GMP in underpinning the recalcitrant pathobiology of A. baumannii and also reveals PdeD as a potential novel therapeutic target.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.